Creating a database for patients with mesonephric-like adenocarcinoma
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
M.D. Anderson Cancer Center · NCT06377527
This study is creating a detailed database of information about patients with mesonephric-like adenocarcinoma to help researchers better understand this rare type of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06377527 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a comprehensive database of medical information for patients diagnosed with mesonephric-like adenocarcinoma (MLA), the rarest form of endometrial carcinoma. It will collect both prospective and retrospective data on patient characteristics, disease details, treatment, and outcomes. The goal is to organize this clinical information to support future research and enhance understanding of MLA. The data will be securely stored and serve as a valuable resource for ongoing and future studies.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with gynecologic mesonephric-like adenocarcinoma or related conditions.
Not a fit: Patients with other subtypes of endometrial adenocarcinomas will not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could lead to improved understanding and treatment options for patients with mesonephric-like adenocarcinoma.
How similar studies have performed: While this approach is focused on a rare cancer type, similar registries have shown success in enhancing understanding and treatment of other rare conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients over the age of 18. 2. Patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA), mesonephric adenocarcinoma (MA), mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas. 3. For patients who provide consent, they must speak and/or read English or Spanish. Exclusion Criteria: 1. Patients with other subtypes of EACs. 2. Patients who are considered cognitively impaired. Assessment will be obtained based on their need of a Legally Authorized Representative.
Where this trial is running
Houston, Texas
- MD Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Jeffrey How, MD — M.D. Anderson Cancer Center
- Study coordinator: Jeffrey How, MD
- Email: askmdanderson@mdanderson.org
- Phone: 877-632-6789
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mesonephric-like Adenocarcinoma